Suven Life Sciences Limited (BOM:530239)
152.20
-4.40 (-2.81%)
At close: Feb 12, 2026
Suven Life Sciences Revenue
Suven Life Sciences had revenue of 28.09M INR in the quarter ending December 31, 2025, with 74.46% growth. This brings the company's revenue in the last twelve months to 70.62M, down -6.77% year-over-year. In the fiscal year ending March 31, 2025, Suven Life Sciences had annual revenue of 66.56M, down -43.08%.
Revenue (ttm)
70.62M
Revenue Growth
-6.77%
P/S Ratio
495.99
Revenue / Employee
511.71K
Employees
138
Market Cap
35.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 66.56M | -50.37M | -43.08% |
| Mar 31, 2024 | 116.93M | -19.02M | -13.99% |
| Mar 31, 2023 | 135.95M | 16.44M | 13.76% |
| Mar 31, 2022 | 119.51M | -21.23M | -15.08% |
| Mar 31, 2021 | 140.73M | -6.32M | -4.30% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 22.27B |
| Neuland Laboratories | 15.75B |
| Shilpa Medicare | 14.33B |
| Sudeep Pharma | 6.17B |
| Bajaj HealthCare | 6.12B |
| NGL Fine-Chem | 4.49B |
| Gujarat Themis Biosyn | 1.59B |
| Infinium Pharmachem | 1.57B |
Suven Life Sciences News
- 9 days ago - Pharma sector stocks today, Feb 4: Suven Life Sciences jumps 9%, Aarti Drugs falls 6%, Shilpa Medicare up 2.80%, Mankind Pharma down 2.92% - Business Upturn
- 2 months ago - Suven Life Sciences achieves 100% enrollment for Phase-2b Trial of Ropanicant for major depressive disorder - Business Upturn
- 1 year ago - Suven Life Sciences shares surge over 8% after clinical trial update - Business Upturn
- 1 year ago - Suven Life Sciences initiates Phase-1 clinical trial for SUVN-I6107 - Business Upturn
- 1 year ago - Suven Life Sciences reports positive Phase-2a results for Ropanicant in treating Major Depressive Disorder - Business Upturn
- 1 year ago - Suven Life Sciences announces FDA acceptance of Investigational New Drug - Business Upturn